Last month, an experimental pancreatic cancer drug from Infinity Pharmaceuticals ( INFI) failed a mid-stage study because patients were not living longer. Clovis Oncology ( CLVS) and Celgene ( CELG) are each, separately, conducting studies of pancreatic cancer drugs with results expected later this year.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

One Reason Why Threshold Pharma (THLD) Stock Is Jumping Today

5 Breakout Stocks Under $10 Set to Soar

CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail

2 'Rules of the Road' for Biotech Investing

2 'Rules of the Road' for Biotech Investing